Takeda gets EU green light to keep bowel drug after Shire buy

BRUSSELS (Reuters) - Japan's Takeda Pharmaceutical Co Ltd will be allowed to keep a drug used to treat bowel disease because changes in the market have removed the need to sell it to allay EU antitrust concerns over last year's acquisition of Shire plc.Two years ago, the European Commission ordered the Japanese drugmaker to sell off the biologic drug SHP 647 developed by Shire to treat inflammatory bowel diseases.The EU competition enforcer said on Thursday it had reversed its decision after an..